Canterbury DHB


Acute Bleeding Management

Discuss with the regional haematologist for individual treatment plan.

FVIIa (NovoSeven®) is the recommended initial therapy. For full details, see The Use of NovoSeven®.

Use only at the direction of a specialist haematologist involved with haemophilia care.

Consider FEIBA as an alternative.

Refer to the National Haemophilia Guidelines, page 17, for full details of management of major and minor bleeds in patients with VIII inhibitors. The use of Novo Seven® and FEIBA is described here as well as Immune Tolerance Therapy, IVIg and immunosuppression. Patients with inhibitors to FVIII, either inherited or acquired, present complex problems. Consult the haematologist as soon as possible.

About this Canterbury DHB document (5269):

Document Owner:

Sean Macpherson (see Who's Who)

Last Reviewed:

November 2019

Next Review:

November 2022


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5269